Date | Title | Description | |
---|---|---|---|
15 Mar 2022 | On significant placements in financial instruments | Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
14 Mar 2022 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
Pages
Date | Title | Description | |
---|---|---|---|
13 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 | Download |
06 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 29 November 2021 and 3 December 2021 | Download |
22 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 November 2021 and 19 November 2021 | Download |
16 Nov 2021 | Liquidity and counterparty agreements | The Company informs of the termination of the Liquidity Agreement | Download |
16 Nov 2021 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2021 Capital Markets Day | Download |
Pages
Date | Title | Description | |
---|---|---|---|
04 Apr 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2019 | Download |
19 Mar 2019 | R&D: new licenses, patents and registered trademarks | ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia | Download |
26 Feb 2019 | Informe Anual de Remuneraciones de los Consejeros | ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors | Download |
26 Feb 2019 | Informe Anual de Gobierno Corporativo | ROVI releases the 2018 Annual Corporate Governance Report | Download |
26 Feb 2019 | Otros sobre gobierno corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |